JAMA Dermatology

<jats:sec id="ab-doi240057-4"><jats:title>Importance</jats:title><jats:p>Autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear.</jats:p></jats:sec><jats:sec id="ab-doi240057-5"><jats:title>Objective</jats:title><jats:p>To evaluate the incidence and prevalence of ASCVD among those with CLE, SLE, and psoriasis compared with a disease-free control group.</jats:p></jats:sec><jats:sec id="ab-doi240057-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This retrospective, matched longitudinal cohort study used data from January 2018 to December 2020 in the IBM MarketScan Commercial Claims and Encounters Database. The control population included individuals free of CLE, SLE, and psoriasis, matched 10:1 with the CLE population on age, sex, insurance type, and enrollment duration. Data were analyzed from September 2022 to April 2024.</jats:p></jats:sec><jats:sec id="ab-doi240057-7"><jats:title>Main Outcomes and Measures</jats:title><jats:p>Prevalent ASCVD was defined as coronary artery disease, prior myocardial infarction, or cerebrovascular accident. Incident ASCVD was assessed through the number of hospitalization events through the end of follow-up (up to 3 years) in each group. Multivariable logistic regression and Cox proportional hazards models were performed to compare the prevalence and incidence of ASCVD between exposure groups, adjusting for age, sex, and cardiovascular risk factors.</jats:p></jats:sec><jats:sec id="ab-doi240057-8"><jats:title>Results</jats:title><jats:p>A total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24 675 with SLE (median [IQR] age, 46 [36-54] years; 22 432 [91%] female), 192 577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81 380 control individuals (49 [40-57] years; 66 180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; <jats:italic>P</jats:italic> &amp;amp;lt; .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; <jats:italic>P</jats:italic> &amp;amp;lt; .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; <jats:italic>P</jats:italic> = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; <jats:italic>P</jats:italic> &amp;amp;lt; .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; <jats:italic>P</jats:italic> &amp;amp;lt; .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; <jats:italic>P</jats:italic> = .09).</jats:p></jats:sec><jats:sec id="ab-doi240057-9"><jats:title>Conclusions and Relevance</jats:title><jats:p>In this retrospective matched longitudinal cohort study, CLE was associated with an increased risk for ASCVD, similar to the risk in SLE but higher than the risk in psoriasis. The role of comorbidities that augment ASCVD risk like smoking status should be further investigated. Clinicians treating patients with CLE can consider them at increased ASCVD risk and institute appropriate screening tests.</jats:p></jats:sec>

Systemic lupus erythematosus: diagnosis and clinical management.

J Autoimmun

Does treatment of psoriasis reduce the risk of cardiovascular disease?

Drugs

The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis.

Clin Rev Allergy Immunol

Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study.

Arthritis Rheum

Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study.

Arthritis Care Res (Hoboken)

Distinctive cutaneous subsets in the spectrum of lupus erythematosus.

J Am Acad Dermatol

High prevalence of metabolic syndrome in patients with discoid lupus erythematosus: a cross-sectional, case-control study.

J Immunol Res

Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort.

Cardiovasc Diabetol

Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study.

Lupus

Increased risk of cancer among 3663 patients with cutaneous lupus erythematosus: a Swedish nationwide cohort study.

Br J Dermatol

Older black race is a risk factor for metabolic syndrome in cutaneous lupus erythematosus.

Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: a Danish nationwide cohort study.

Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden.

BMC Neurol

Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden.

PLoS One

Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study.

Clin Rheumatol

Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study.

EBioMedicine

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Lancet

The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

PLoS Med

A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data.

Vaccine

Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.

Pharmacoepidemiol Drug Saf

British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021.

Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice.

JAMA Cardiol

Risk of myocardial infarction in patients with psoriasis.

JAMA

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

Risk of cerebrovascular accidents and ischemic heart disease in cutaneous lupus erythematosus: a population-based cohort study.

Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.

Int J Womens Dermatol

Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus.

Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.

Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus.

Arch Dermatol

Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.

Sensitivity of claims-based algorithms to ascertain smoking status more than doubled with meaningful use.

Value Health

Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.

J Am Coll Cardiol

Modular gene analysis reveals distinct molecular signatures for subsets of patients with cutaneous lupus erythematosus.

IFN-a negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus.

J Immunol

Interferon-a priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-a and atherosclerosis in lupus.

Cautions when using race and ethnicity in administrative claims data sets.

JAMA Health Forum

The accuracy of race & ethnicity data in US based healthcare databases: a systematic review.

Am J Surg

Autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear.
To evaluate the incidence and prevalence of ASCVD among those with CLE, SLE, and psoriasis compared with a disease-free control group.
This retrospective, matched longitudinal cohort study used data from January 2018 to December 2020 in the IBM MarketScan Commercial Claims and Encounters Database. The control population included individuals free of CLE, SLE, and psoriasis, matched 10:1 with the CLE population on age, sex, insurance type, and enrollment duration. Data were analyzed from September 2022 to April 2024.
Prevalent ASCVD was defined as coronary artery disease, prior myocardial infarction, or cerebrovascular accident. Incident ASCVD was assessed through the number of hospitalization events through the end of follow-up (up to 3 years) in each group. Multivariable logistic regression and Cox proportional hazards models were performed to compare the prevalence and incidence of ASCVD between exposure groups, adjusting for age, sex, and cardiovascular risk factors.
A total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24 675 with SLE (median [IQR] age, 46 [36-54] years; 22 432 [91%] female), 192 577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81 380 control individuals (49 [40-57] years; 66 180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; P < .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; P < .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; P = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; P < .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; P < .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; P = .09).
In this retrospective matched longitudinal cohort study, CLE was associated with an increased risk for ASCVD, similar to the risk in SLE but higher than the risk in psoriasis. The role of comorbidities that augment ASCVD risk like smoking status should be further investigated. Clinicians treating patients with CLE can consider them at increased ASCVD risk and institute appropriate screening tests.

Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus.

Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus

Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions